Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Spinal Diseases: HELP
Articles by Anonymous1170835
Based on 1 article published since 2009
(Why 1 article?)

Between 2009 and 2019, Anonymous1170835 wrote the following article about Spinal Diseases.
+ Citations + Abstracts
1 Clinical Trial Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. 2015

McInnes, Iain B / Mease, Philip J / Kirkham, Bruce / Kavanaugh, Arthur / Ritchlin, Christopher T / Rahman, Proton / van der Heijde, Désirée / Landewé, Robert / Conaghan, Philip G / Gottlieb, Alice B / Richards, Hanno / Pricop, Luminita / Ligozio, Gregory / Patekar, Manmath / Mpofu, Shephard / Anonymous1170835. ·Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK. Electronic address: Iain.McInnes@glasgow.ac.uk. · Swedish Medical Center and University of Washington, Seattle, WA, USA. · Guy's and St Thomas' NHS Foundation Trust, London, UK. · Department of Internal Medicine, Division of Rheumatology, Allergy and Immunology, University of California San Diego School of Medicine, San Diego, CA, USA. · Allergy/Immunology and Rheumatology Division, University of Rochester, Rochester, NY, USA. · Memorial University, Newfoundland, NL, Canada. · Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands. · Amsterdam Rheumatology and Immunology Center, Amsterdam, and Atrium Medical Center, Heerlen, Netherlands. · NIHR Leeds Musculoskeletal Biomedical Research Unit and University of Leeds, Leeds, UK. · Department of Dermatology, Tufts Medical Center, Boston, MA, USA. · Novartis Pharma, Basel, Switzerland. · Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA. · Novartis Healthcare, Hyderabad, India. ·Lancet · Pubmed #26135703.

ABSTRACT: BACKGROUND: Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis. METHODS: In this phase 3, double-blind, placebo-controlled study undertaken at 76 centres in Asia, Australia, Canada, Europe, and the USA, adults (aged ≥18 years old) with active psoriatic arthritis were randomly allocated in a 1:1:1:1 ratio with computer-generated blocks to receive subcutaneous placebo or secukinumab 300 mg, 150 mg, or 75 mg once a week from baseline and then every 4 weeks from week 4. Patients and investigators were masked to treatment assignment. The primary endpoint was the proportion of patients achieving at least 20% improvement in the American College of Rheumatology response criteria (ACR20) at week 24. Analysis was by intention to treat. This study is registered with ClinicalTrials.gov, number NCT01752634. FINDINGS: Between April 14, and Nov 25, 2013, 397 patients were randomly assigned to receive secukinumab 300 mg (n=100), 150 mg (n=100), 75 mg (n=99), or placebo (n=98). A significantly higher proportion of patients achieved an ACR20 at week 24 with secukinumab 300 mg (54 [54%] patients; odds ratio versus placebo 6·81, 95% CI 3·42-13·56; p<0·0001), 150 mg (51 [51%] patients; 6·52, 3·25-13·08; p<0·0001), and 75 mg (29 [29%] patients; 2·32, 1·14-4·73; p=0·0399) versus placebo (15 [15%] patients). Up to week 16, the most common adverse events were upper respiratory tract infections (four [4%], eight [8%], ten [10%], and seven [7%] with secukinumab 300 mg, 150 mg, 75 mg, and placebo, respectively) and nasopharyngitis (six [6%], four [4%], six [6%], and eight [8%], respectively). Serious adverse events were reported by five (5%), one (1%), and four (4%) patients in the secukinumab 300 mg, 150 mg, and 75 mg groups, respectively, compared with two (2%) in the placebo group. No deaths were reported. INTERPRETATION: Subcutaneous secukinumab 300 mg and 150 mg improved the signs and symptoms of psoriatic arthritis, suggesting that secukinumab is a potential future treatment option for patients with this disorder. FUNDING: Novartis.